Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)

Cited by (322)

Items 201–300 of 322

1. From Anti-PD-1/PD-L1 to CTLA-4 and to MUC1—Is the Better Response to Treatment in Smokers of Cancer Patients Drug Specific?
   Lishi Wang, Fengxia Liu, Jing Li, Li Ma, Helin Feng, Qingyi Liu, William Chi Shing Cho, Haiyong Chen, Hong Chen, Hua Guo et al. · 2021 · Journal of Personalized Medicine
2. Phase II Study of a Non-Platinum–Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas
   Maria Catherine Pietanza, Matthew David Hellmann, John Joseph Fiore, Stephanie Smith–Marrone, Ethan Basch, Lawrence Howard Schwartz, Michelle S. Ginsberg, Marwan Shouery, Samantha Kass Newman, Mary Shaw et al. · 2016 · Journal of Thoracic Oncology
3. Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202)
   Akihiko Miyanaga, Kaoru Kubota, Yukio Hosomi, Yusuke Okuma, Koichi Minato, Sakae Fujimoto, Hiroaki Okamoto, Miyako Satouchi, Hiroshi Isobe, Hiromi Aono et al. · 2019 · Japanese Journal of Clinical Oncology
4. The influence of pemetrexed-based continuous maintenance therapy on survival of locally advanced and metastatic lung adenocarcinoma
   Yu Huang, Ying Wang, Dandan Hu, Lingjuan Chen, Ruiguang Zhang, Shishi Cheng, Gang Wu, Xiaorong Dong · 2019 · Annals of Translational Medicine
5. Nitroglycerin-induced downregulation of AKT- and ERK1/2-mediated radiation-sensitive 52 expression to enhance pemetrexed-induced cytotoxicity in human lung cancer cells
   Jen‐Chung Ko, Jyh‐Cheng Chen, Pei-Yu Tseng, Jou-Min Hsieh, Chen-Shan Chiang, Liling Liu, Chin-Cheng Chien, I-Hsiang Huang, Yun‐Wei Lin · 2022 · Toxicology Research
6. Extended use of rh-endostatin improves prognosis in patients with advanced non-small cell lung cancer: an analysis of retrospective study
   Jing Zhao, Yi Cheng, Liting He, Jianhua Wang, Qingsong Xi, Chen Gong · 2022 · Journal of Thoracic Disease
7. Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study
   Koji Nishimoto, Masato Karayama, Naoki Inui, Hideki Yasui, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Noriyuki Enomoto, Yutaro Nakamura et al. · 2018 · Medical Oncology
8. Real world efficacy of immunotherapy in nonsmall cell lung cancer
   Fedor Vladimirovich Moiseenko, Никита Михайлович Волков, Nuriniso Kh. Abduloeva, Н. В. Левченко, Viacheslav A Chubenko, Альбина Сергеевна Жабина, V. V. Chernobrivceva, T. N. Shuginova, Ksenya V. Shelekhova, Valeriia A. Kheinshtein et al. · 2020 · Malignant tumours
9. Safety and efficacy of pemetrexed for patients with non-small cell lung cancer in the setting of renal impairment: a retrospective study
   Yusuke Shima, Hironori Yoshida, Keiichiro Suminaga, Hiroshi Yoshida, Kentaro Hashimoto, Tatsuya Ogimoto, Kazutaka Hosoya, Hitomi Ajimizu, Tomoko Yamamoto Funazo, Takashi Nomizo et al. · 2025 · BMC Cancer
10. From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?
    Ettore D’Argento, Sabrina Rossi, Giovanni Schinzari, Antonia Strippoli, Michele Basso, Alessandra Cassano, Carlo Barone · 2016 · Current Treatment Options in Oncology
11. Clinical Relevance of Alternative Endpoints in Colorectal Cancer First-Line Therapy With Bevacizumab: A Retrospective Study
    Anthony Turpin, Sophie Paget‐Bailly, Anne Ploquin, Antoine Hollebecque, Charlotte Peugniez, Farid El-Hajbi, Franck Bonnetain, Mohamed Hebbar · 2017 · Clinical Colorectal Cancer
12. [Review on the Combination Strategy of Anti-angiogenic Agents and Other Anti-tumor Agents in Advanced Non-small Cell Lung Cancer].
    Ziyi Xu, Junling Li · 2021 · PubMed Central
13. Rola systemowych metod leczenia u chorych na niedrobnokomórkowego raka płuca i złośliwego międzybłoniaka opłucnej: Uaktualnione zalecenia ekspertów
    Jacek Jassem, Wojciech Biernat, Maciej Bryl, Joanna Chorostowska‐Wynimko, Rafał Dziadziuszko, Paweł Adam Krawczyk, Radzisław Kordek, Dariusz Mirosław Kowalski, Maciej Jerzy Krzakowski, Wlodzimierz Tadeusz Olszewski et al. · 2014 · Advances in respiratory medicine
14. Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma
    Norimichi Akiyama, Masato Karayama, Naoki Inui, Hideki Yasui, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Noriyuki Enomoto, Yutaro Nakamura et al. · 2019 · Investigational New Drugs
15. Lung Cancer: Diagnosis and Treatment Approach
    Apichat Tantraworasin, Thatthan Suksomboonchroen, Yutthaphan Wannasopha, Sarawut Kongkarnka, Somcharoen Saeteng, Nirush Lertprasertsuke, Juntima Euathrongchit, Busayamas Chewaskulyong · 2015 · Springer eBooks
16. Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy
    Javier de Castro, J.L. González-Larriba, Sergio Vázquez‐Estévez, Bartomeu Massutí, J.M. Sánchez-Torres, Manuel Dómine, Pilar Garrido, Antonio Calles, Angel Artal, Ricardo Collado et al. · 2016 · Clinical & Translational Oncology
17. Increased risk of severe infections in non-small-cell lung cancer patients treated with pemetrexed: a meta-analysis of randomized controlled trials
    Song Tong, Kai Fan, Ke Jiang, Wei Zhai, Bin Fang, Sihua Wang, Jianjun Wang · 2016 · Current Medical Research and Opinion
18. Angiogenesis inhibition in lung cancer: emerging novel strategies.
    Chiara Lazzari, Alessandra Bulotta, Giuseppe Damiano, Aurora Mirabile, Mariagrazia Viganó, Giulia Veronesi, Vanesa Gregorc · 2022 · PubMed
19. The Use of Systemic Treatment in the Maintenance of Patients with Non-small Cell Lung Cancer
    S. Kulkarni, Emily T. Vella, Nadia Coakley, Shi‐Bo Cheng, Richard William Gregg · 2015
20. Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients
    Bo Jia, Zhi Dong, Di Wu, Jun Zhao, Meina Wu, Tongtong An, Yuyan Wang, Minglei Zhuo, Jianjie Li, Yang Wang et al. · 2020 · Cancer Cell International
21. Immune Therapy
    Lysanne A. Lievense, Joachim G.J.V. Aerts, Joost P. Hegmans · 2015 · Advances in experimental medicine and biology
22. Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME database
    Mathilde Cabart, Loı̈c Mourey, Dominique Pasquier, Sophie Schneider, H. Léna, Nicolas Girard, CHRISTOS CHOUAID, Roland Schött, Sandrine Hiret, Didier Debieuvre et al. · 2024 · Journal of Geriatric Oncology
23. First‐line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non‐squamous non‐small cell lung cancer with wild‐type driver genes: A real‐world study in China
    Qing Chang, Yanwei Zhang, Jianlin Xu, Runbo Zhong, Huiping Qiang, Bo Zhang, Baohui Han, Jialin Qian, Tianqing Chu · 2019 · Thoracic Cancer
24. Focus on Recommendations for the Management of Non-small Cell Lung Cancer
    Pernelle Lavaud, Benjamin Besse, Thierry de Baère, Frédèric Deschamps, Sacha Mussot, Cecile Le Pechoux, Caroline Caramella, Olaf M Mercier, Laura Mezquitta, Angela Botticella et al. · 2019 · CardioVascular and Interventional Radiology
25. [Progress of Bevacizumab in the Front-line Treatment of Advanced Non-small Cell Lung Cancer].
    Bin Ai, Yifan Yang · 2020 · PubMed Central
26. Cytotoxic Chemotherapy for Non-small Cell Lung Cancer
    Byeong-Bae Park · 2014 · Hanyang Medical Reviews
27. Defining the Issues in the Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer
    Ajeet Gajra · 2015 · Lung Cancer Management
28. Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective
    Nicolas Girard · 2013 · Expert Review of Anticancer Therapy
29. Efficacy of third-line pemetrexed monotherapy versus pemetrexed combination with bevacizumab in patients with advanced EGFR mutation-positive lung adenocarcinoma.
    Chengzhi Zhou, Yin-Yin Qin, Zhanhong Xie, Jiexia Zhang, Ming Ouyang, Shiyue Li, Rongchang Chen · 2014 · Europe PMC (PubMed Central)
30. Pemetrexed as indispensable drug for the treatment of non-squamous non-small cell lung cancer; the role in induction and maintenance therapy
    2014 · Cancer Cell & Microenvironment
31. Les cancers bronchiques non à petites cellules de stade IV Hors addiction oncogénique : 1re ligne et maintenance
    Pierre Jean Souquet, S. Couraud, Myriam Locatelli-Sanchez · 2016 · Revue des Maladies Respiratoires Actualités
32. Kinetic change of serum carcinoembryonic antigen can early predict progression in patients with metastatic non-small cell lung cancer during maintenance therapy with bevacizumab plus pemetrexed
    Nasha Zhang, Li Kong, Fang Shi, Jing Wang, Haiyong Wang, Ming Yang, Jinming Yu, Hui Zhu · 2017 · Oncotarget
33. Targeting angiogenesis in lung cancer
    Sameh Daher, Jair Bar · 2018 · memo - Magazine of European Medical Oncology
34. The Role of Anti-Angiogenic Agents (VEGF)
    Melinda E. Oliver, Elizabeth S. Waxman · 2019 · Springer eBooks
35. Treatment with or without bevacizumab as a first‐line and maintenance therapy for advanced non‐squamous non‐small cell lung cancer: A retrospective study
    Jun Ni, Wang Hanping, Xiaoyan Si, Yan Xu, Mengzhao Wang, Xiaotong Zhang, Zhang Li · 2020 · Thoracic Cancer
36. Doublet vs Single-Agent Maintenance Therapy in the Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis
    Jing Qi, Xiuzhi Guo, Aihua Li · 2020 · Drug Design Development and Therapy
37. Tratamiento de cáncer de pulmón metastásico (estadio IV) de célula no pequeña : consenso de expertos, Asociación Colombiana de Hematología y Oncología (ACHO).
    Aylen Vanessa Ospina, Ricardo Elias Bruges, Mauricio Lema, Gilberto De Lima Lopes Jr., Rodolfo Gómez, Milton Lombana, Carlos Vargas, Ricardo Duarte, José Fernando Lobatón, Andrés Yepes et al. · 2018 · Revista Colombiana de Hematología y Oncología
38. Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR‐mutated advanced non‐small‐cell lung
    Chia‐Yu Kuo, Ming‐Ju Tsai, Jen‐Yu Hung, Mei‐Hsuan Lee, Kuan‐Li Wu, Yu‐Chen Tsai, Cheng‐Hao Chuang, Chung-Wen Huang, Chin‐Ling Chen, Chih‐Jen Yang et al. · 2024 · The Kaohsiung Journal of Medical Sciences
39. Maintenance therapy with anlotinib after induction therapy with platinum-based chemotherapy for advanced non-small-cell lung cancer: A pooled analysis of 2 single-arm trials
    Yiqian Liu, Liyun Miao, Xiao Chen, Xiaoli Zhu, Yan Li, Jingdong He, Ping Chen, Shengbin Dai, Ziling Liu, Kewei Ma et al. · 2024 · Medicine
40. Moving molecularly directed therapies to the first-line in ALK-positive lung cancer: crizotinib is just the beginning.
    Samuel Jacob Klempner, Alexander Grenander Raufi, Sai‐Hong Ignatius Ou · 2015 · PubMed Central
41. The optimal timing and courses of bevacizumab added to chemotherapy for non-squamous non-small cell lung cancer: revelations from the real-world experience in a single Chinese cancer center
    Qianqian Long, Yu Feng, Chang Liu, Xianghua Wu, Huijie Wang, Hui Yu, Xinmin Zhao, Jialei Wang · 2020 · Annals of Translational Medicine
42. Factors correlating with shorter survival after treatment: aiding oncologists to choose who (not) to receive palliative systemic therapy
    Pui Ying Patty Ho, Victor Ho-Fun Lee · 2019 · Annals of Palliative Medicine
43. Pathologic Response and Survival after Neoadjuvant Chemotherapy with Bevacizumab Followed by Surgery for Clinical Stage II/IIIA Nonsquamous Non-Small-Cell Lung Cancer: Results from a Phase II Feasibility Study (NAVAL)
    Yasuhiro Tsutani, Yoshihiro Miyata, Kenji Suzuki, Fumihiro Tanaka, Hiroyuki Ito, Yoshinori Yamashita, Morihito Okada · 2024 · Cancers
44. Improving lung cancer decision-making using a conversation tool (iDECIDE): a stepped wedge pragmatic clinical trial
    Natalie G. Disher, Nathan F. Dieckmann, James Case, Felipe Rubim, Karen Eden, Sara E. Golden, Daniel D. Matlock, Clifford A. Coleman, Karen S. Lyons, Somnath Saha et al. · 2025 · Future Oncology
45. Maintenance therapy in NSCLC
    Thomas Brodowicz · 2012 · memo - Magazine of European Medical Oncology
46. Molecular Targeted Therapy in Lung Cancer
    Myung‐Ju Ahn · 2014 · Hanyang Medical Reviews
47. How many drugs in the maintenance setting for non-small-cell lung cancer? For what benefit?
    Alain Vergnenégre · 2013 · PubMed
48. An exceptional overall survival using bevacizumab beyond progression in a patient with non-small cell lung cancer
    Giandomenico Roviello, Edoardo Francini, Armando Perrella, Letizia Laera, Maria Antonietta Mazzei, Susanna Guerrini, Roberto Petrioli · 2015 · Cancer Biology & Therapy
49. Maintenance Chemotherapy for Advanced Non-small Cell Lung Cancer
    Makoto Nishio · 2014 · Haigan
50. Medikamentöse Therapie des metastasierten oder rezidivierten mutationsnegativen NSCLC
    Achim Rittmeyer · 2018 · Der Onkologe
51. A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL)
    Naoyuki Nogami, Toshio Kubo, Akihiro Bessho, Makoto Sakugawa, Satoshi Ikeo, Toshihide Yokoyama, Nobuhiko Seki, Ryosuke Ochiai, Nobukazu Fujimoto, Shuji Murakami et al. · 2024 · Japanese Journal of Clinical Oncology
52. Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea
    Jaemin Jo, Jung Ho Kim, Ji Young Kim, Chang Lim Hyun, Jiyoung Rhee, Jung-Mi Kwon, Sang Hoon Han, Woo-Kun Kim · 2015 · Cancer Research and Treatment
53. Épidémiologie du cancer bronchique : des considérations générales à l’aspect moléculaire
    Julien Mazières · 2014 · Revue des Maladies Respiratoires Actualités
54. Assessment of chemotherapy strategy using bevacizumab for non-squamous non-small cell lung cancer in a real-world setting: A multi-institutional observational study
    Masayoshi Higashiguchi, Takashi Kijima, Osamu Morimura, Akio Osa, Hidekazu Suzuki, Takako Inoue, Hiroyuki Kagawa, Kiyonobu Ueno, Tomonori Hirashima, Toru Kumagai et al. · 2015 · Cancer Treatment Communications
55. Inhibition of Tumor Angiogenesis in the Treatment of Lung Cancer
    Massimo Di Maïo, Silvia Novello, Enrica Capelletto, Giorgio V. Scagliotti · 2017 · Springer eBooks
56. Management of Advanced Non–Small Cell Lung Cancer
    Bing Xia, Roy S. Herbst · 2018 · Elsevier eBooks
57. First-Line Therapy for Wild-Type Patients
    Michael J. Jelinek, Jyoti D. Patel · 2018 · Elsevier eBooks
58. Tolerance and efficacy of branded generic pemetrexed maintenance in Indian patients of metastatic non-squamous non-small-cell lung cancer
    Amit Sehrawat, K M Parthasarathy, Deni Gupta, Arun Gera · 2019 · Indian Journal of Cancer
59. Intestinal Perforation due to Neutropenic Enterocolitis in a Patient Treated with Bevacizumab for Ovarian Cancer
    Akinori Sasaki, Kenichi Harano, Takahiro Kogawa, Nobuaki Matsubara, Yoichi Naito, Ako Hosono, Hirofumi Mukai, Takayuki Yoshino, Toru Mukohara · 2020 · Case Reports in Oncological Medicine
60. Cancer Immunotherapy Confers a Global Benefit
    Zahra Aryan, Mahsa Keshavarz‐Fathi, Håkan Mellstedt, Nima Rezaei · 2020 · Springer eBooks
61. Reply to S. Barni et al, K.R. Dearing et al, and N. Murray
    Luis G Paz-Ares, Filippo de Marinis, Carla Visseren‐Grul, Cesare Gridelli · 2014 · Journal of Clinical Oncology
62. When the Abstract Reports a Well-Tolerated Treatment, the Data Should Support It
    Bruno M. Strebel · 2013 · Journal of Clinical Oncology
63. Editorial on “The AvaALL Randomized Clinical Trial”
    Laura Bonanno, Alberto Pavan, Giulia Pasello, Stefano Indraccolo · 2019 · Journal of Thoracic Disease
64. Malignome des Respirationstrakts
    Alexander H. Schmittel · 2012 · Elsevier eBooks
65. Antiangiogenic Agents in Lung Cancer: Lost Cause or Flicker of Hope?
    Benjamin Philip Levy, Jean Y. H. Lee, Daniel Jacob Becker · 2015 · American Journal of Hematology / Oncology®
66. Agents in the preclinical development stage for non-small cell lung cancer
    Paola Claudia Sacco, Assunta Sgambato, Francesca Casaluce, Paolo Maione, Antônio Rossi, Giovanni Palazzolo, Alba Napolitano, Cesare Gridelli · 2015 · Expert Review of Anticancer Therapy
67. Bevacizumab combined with pemetrexed plus cisplatin followed by maintenance bevacizumab/pemetrexed as first-line treatment of advanced non-squamous non-small cell lung cancer: A single-arm Phase 2 study
    Armando Santoro, Gunnar Hillerdal, Gert Hoeffken, Adolfo Gino Favaretto, R.P. Carrion, Carla Visseren‐Grul, Sophie Ameryckx, Karin Helsberg, Victoria Soldatenkova, Nawel Bourayou et al. · 2014 · Lung Cancer
68. Reply to B.M. Strebel
    Fabrice Barlési, Arnaud Scherpereel, Achim Rittmeyer, Antonio Pazzola, Joo-Hang Kim, Myung‐Ju Ahn, Joachim G.J.V. Aerts, Anders Vikström, Harry J.M. Groen · 2013 · Journal of Clinical Oncology
69. Stratégie de maintenance dans les carcinomes bronchiques non à petites cellules de stade IV
    Vincent Bunel, Maurice Pérol · 2014 · Revue des Maladies Respiratoires Actualités
70. Reply to M. Roschewski et al
    Nikhil C. Munshi, Kenneth Carl Anderson · 2014 · Journal of Clinical Oncology
71. Mise au point 2014 du cancer bronchique non à petites cellules (en dehors du dépistage)
    Valérie Gounant, Antoine Khalil, Perrine Créquit, A. Lavolé, Anne-Marie Ruppert, Martine Antoine, Bernard J. Milleron, Marie Wislez, Marie France Carette, Jalal Assouad et al. · 2014 · Journal de radiologie diagnostique et interventionnelle
72. How Should We Manage Bevacizumab Toxicity in Lung Cancer Patients?
    Olivier Huillard, Cécile Defaucheux, Jeanne Chapron, Daniel J. Dusser, Pascaline Boudou, Jérôme Alexandre, François Goldwasser · 2014 · Lung Cancer Management
73. The treatment of advanced non-small-cell lung cancer with anaplastic lymphoma kinase genetic alterations: reality and hopes
    Assunta Sgambato, Francesca Casaluce, Antônio Rossi, Paolo Maione, Paola Claudia Sacco, Fortunato Ciardiello, Cesare Gridelli · 2015 · Clinical Investigation
74. Focus on maintenance therapy in non-small-cell lung cancer
    Alfredo Tartarone · 2015 · Future Oncology
75. Evaluating the Utility of Local Therapy for Oligometastatic Lung Cancer
    Tokujiro Yano · 2014 · Lung Cancer Management
76. Personalized maintenance therapy in advanced non-small cell lung cancer.
    Kazuhiro Asami, Kyoichi Okishio, Tomoya Kawaguchi, Shinji Atagi · 2013 · Europe PMC (PubMed Central)
77. Traitement de 1re ligne des cancers bronchopulmonaires non à petites cellules de stade IV en l'absence d'addiction oncogénique
    Maurice Pérol, Virginie Avrillon · 2015 · Revue des Maladies Respiratoires Actualités
78. Antiangiogéniques en cancérologie thoracique : critères de prescription et gestion des effets indésirables
    Solenn Brosseau, Charles Naltet, Valérie Gounant, Gérard Zalcman · 2015 · Revue des Maladies Respiratoires Actualités
79. Cancer Immunotherapy Confers a Global Benefit
    Zahra Aryan, Håkan Mellstedt, Nima Rezaei · 2015 · Springer eBooks
80. Harnessing the antitumor immunity cycle to treat lung cancer
    Myriam Delaunay, Julien Mazières, Nicolas Marie Guibert · 2016 · Current Pulmonology Reports
81. [Treatment progress for EGFR wild-type advanced non-small cell lung cancer].
    Feng Ma, Xiaoyu Shi, Wei Meng, Jing Zhang, Lixia Zhao, Xiaohua He, Junfeng Zhao · 2014 · Europe PMC (PubMed Central)
82. Einfache oder doppelte Erhaltungstherapie?
    Andreas Fischer · 2013 · Im Focus Onkologie
83. Dual-Maintenance Therapy for Advanced Non–Small-Cell Lung Cancer
    Anne S. Tsao · 2013 · Journal watch
84. 3. Chemotherapy for Patients with Non-small Cell Lung Cancer, 1) Cytotoxic Drug Treatment, Maintenance Therapy, and Secondary Line Treatment
    Kazuhisa Takahashi · 2014 · Nihon Naika Gakkai Zasshi
85. Final Results of a Phase II Study of Bevacizumab, Cisplatin and Pemetrexed as First-Line Therapy for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer
    Guillermo López-Vivanco, Eider Azkona, Sergio Carrera, Aintzane Sancho, Itziar Rubio, Juan Manuel Mañé, Begoña Calvo, Unai Aresti, Aitziber Buqué, Inés Marrodán et al. · 2016 · Journal of Cancer Therapy
86. Rola systemowych metod leczenia u chorych na niedrobnokomórkowego raka płuca i złośliwego międzybłoniaka opłucnej: uaktualnione zalecenia ekspertów
    Jacek Jassem, Wojciech Biernat, Maciej Bryl, Joanna Chorostowska‐Wynimko, Rafał Dziadziuszko, Paweł Adam Krawczyk, Radzisław Kordek, Dariusz Mirosław Kowalski, Maciej Jerzy Krzakowski, Wlodzimierz Tadeusz Olszewski et al. · 2014 · Nowotwory Journal of Oncology
87. VII. Developments of Chemotherapy and Improvements of Prognosis in Lung Cancer
    Akira Inoue · 2016 · Nihon Naika Gakkai Zasshi
88. Analysis of the Efficacy of Apatinib in the Treatment of Brain Metastases of Lung Adenocarcinoma
    金龙 祝 · 2017 · Asian Case Reports in Oncology
89. Traitement de première ligne et de maintenance dans les CBNPC avancés en l’absence d’addiction oncogénique
    Maurice Pérol, Valérie Paulus, Aurélie Swalduz, Virginie Avrillon · 2017 · Revue des Maladies Respiratoires Actualités
90. Angiogenesis inhibitors and vascular-disrupting agents for non-small-cell lung cancer
    Adam T. McGeoch · 2014
91. Systemtherapie des nichtkleinzelligen Lungenkarzinoms im metastasierten Stadium
    Niels Reinmuth, Amanda Tufman, Martin B. Steins, Martin Reck · 2014 · Der Onkologe
92. A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101)
    Taichi Takashina, Hajime Asahina, Satoshi Oizumi, Noriyuki Yamada, Masao Harada, Kei Takamura, Hiroshi Yokouchi, Toshiyuki Harada, Osamu Honjo, Takahiro Ogi et al. · 2018 · International Journal of Clinical Oncology
93. Chimiothérapie de première ligne incluant le traitement de maintenance et les anti-angiogéniques dans les CBNPC avancés en l’absence d’addiction oncogénique
    Maurice Pérol, Aurélie Swalduz, Valérie Paulus, Virginie Avrillon · 2018 · Revue des Maladies Respiratoires Actualités
94. Maintenance Chemotherapy for Nonsmall Cell Lung Cancer
    Maurice Pérol, Heather A. Wakelee, Luis G Paz-Ares · 2018 · Elsevier eBooks
95. Recent Progress and Prospects of Medical Therapy for Lung Cancer
    Noriaki Takahashi · 2018 · Journal of Nihon University Medical Association
96. Medikamentöse Therapie des metastasierten oder rezidivierten mutationsnegativen NSCLC
    Achim Rittmeyer · 2019 · Wiener klinisches Magazin
97. Targeting Angiogenesis in Malignant Pleural Mesothelioma
    Arnaud Scherpereel · 2019 · Springer eBooks
98. Traitements de première ligne dans les CBNPC avancés, en l’absence d’addiction oncogénique (incluant le traitement de maintenance et les anti-angiogéniques)
    Solenn Brosseau, Valérie Gounant, Aurélie Swalduz, Virginie Avrillon, Maurice Pérol, Gérard Zalcman · 2019 · Revue des Maladies Respiratoires Actualités
99. Radiologic Complete Response In Lung Adenocarcinoma With Symptomatic Brain Metastasis After Systematic Therapy: A Case Study
    Jianxin Chen, Junhui Wang, Qinhong Zheng, Meiling Weng, Xilin Wu · 2019 · OncoTargets and Therapy
100. Paclitaxel as a possible continuation maintenance therapy in advanced non-small-cell lung cancer
     Suzy Fawzy Gohar, Amira H Hegazy, Suzan Ahmed Alhassanin, Mohamed Shehata, Naser Abd El Bary, Khaled Abd El Aziz · 2020 · International Journal of Cancer and Biomedical Research